Redwood Pharma Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Redwood Pharma
Access all reports
Redwood Pharma AB focuses on developing innovative ophthalmic therapies, particularly for dry eye disease (DED). Utilizing its patented IntelliGel technology, the company aims to enhance drug delivery, allowing for reduced dosages and decreased dosing frequency, thus minimizing potential systemic toxicities. Redwood Pharma's strategy involves early-stage clinical development with the intent to license its products to larger pharmaceutical firms for global distribution. Redwood Pharma is headquartered in Stockholm, Sweden, and its shares are listed on the Nasdaq Stockholm.
Latest articles
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Walmart: Walton, Retailing, and Everyday Low Prices
Walmart was founded in 1962 by Sam Walton, and has grown to become the largest retailer in the world, employing more than 2.1 million people worldwide.
17 Oct 2024
Ticker symbol
REDW
Country
đžđȘ Sweden